SK bioscience Co.,Ltd. (KRX:302440)
South Korea flag South Korea · Delayed Price · Currency is KRW
38,900
-700 (-1.77%)
Last updated: May 7, 2025

SK bioscience Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
267,545369,506456,726929,001
Other Revenue
---0-
Revenue
267,545369,506456,726929,001
Revenue Growth (YoY)
-27.59%-19.10%-50.84%-
Cost of Revenue
237,466227,681217,443358,968
Gross Profit
30,079141,824239,283570,033
Selling, General & Admin
87,05660,84161,80146,027
Research & Development
71,35385,74357,96047,250
Other Operating Expenses
1,2741,417664.99388.56
Operating Expenses
168,511153,812124,26995,813
Operating Income
-138,431-11,988115,014474,220
Interest Expense
-3,685-1,398-2,461-3,427
Interest & Investment Income
6,97813,5554,8541,517
Currency Exchange Gain (Loss)
3,13713,32516,506-1,662
Other Non Operating Income (Expenses)
4,474-18,722-28,620-434.77
EBT Excluding Unusual Items
-127,527-5,228105,293470,212
Gain (Loss) on Sale of Investments
24,16213,77736,875892.14
Gain (Loss) on Sale of Assets
14,259-68.06-434.623.62
Asset Writedown
-1.41-1,154--
Pretax Income
-89,1077,327141,733471,128
Income Tax Expense
-38,990-14,99019,281115,989
Earnings From Continuing Operations
-50,11722,318122,452355,139
Minority Interest in Earnings
-3,764---
Net Income
-53,88122,318122,452355,139
Net Income to Common
-53,88122,318122,452355,139
Net Income Growth
--81.77%-65.52%-
Shares Outstanding (Basic)
77777773
Shares Outstanding (Diluted)
77777774
Shares Change (YoY)
0.24%-0.01%4.32%-
EPS (Basic)
-697.93290.651596.184844.07
EPS (Diluted)
-698.00290.001590.004810.00
EPS Growth
--81.76%-66.94%-
Free Cash Flow
-292,433-14,114-197,951493,686
Free Cash Flow Per Share
-3787.93-183.27-2570.086686.61
Gross Margin
11.24%38.38%52.39%61.36%
Operating Margin
-51.74%-3.24%25.18%51.05%
Profit Margin
-20.14%6.04%26.81%38.23%
Free Cash Flow Margin
-109.30%-3.82%-43.34%53.14%
EBITDA
-89,20622,777142,250492,995
EBITDA Margin
-33.34%6.16%31.15%53.07%
D&A For EBITDA
49,22534,76527,23618,775
EBIT
-138,431-11,988115,014474,220
EBIT Margin
-51.74%-3.24%25.18%51.05%
Effective Tax Rate
--13.60%24.62%
Advertising Expenses
2,2961,8491,1901,909
Source: S&P Global Market Intelligence. Standard template. Financial Sources.